Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents
Status:
Completed
Trial end date:
2009-04-26
Target enrollment:
Participant gender:
Summary
The objective of this study is to characterize the pharmacokinetic (PK) profile of
brompheniramine maleate (BROM) in children and adolescents, ages 2 to less than 18 years
following dosing in accordance with current weight-age dosing guidelines. Once characterized,
the PK data will be pooled with adult PK data from other studies and analyzed under a
separate analysis plan to confirm or refine the existing OTC doses in children aged 2 to <12
yrs and adolescents aged 12 to <18 yrs.